For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
With sadness CCTG acknowledges the passing of one of our influential international research partners, Mr Russell Conley. Russell was Chief Executive Officer of the Australasian Gastro-Intestinal Trials Group (AGITG) and the GI Cancer Institute for 22 years. He was instrumental in all of the growing list of CCTG and AGITG GI collaborations, including CO.17, CO.20, CO.23, CO.29, NE.2 as well as the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETs).
The recently opened CCTG PR25 clinical trial uses a personalized medicine approach to investigate and evaluate markers to determine which metastatic prostate cancer patients would benefit from treatment with carboplatin a drug used in other cancers but not routinely used in prostate cancer.
The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the CRA Executive as well as the Gynecology and Supportive Care Disease Site Committees.
